查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1555727

无菌注射药物市场，按药物类型、给药途径、药物类别、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Sterile Injectable Drugs Market, By Drug Type, By Route of Administration, By Drug Class, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 393 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年无菌注射药物市场规模为5,851.2376亿美元，2024年至2032年复合年增长率为7.5%。

无菌注射药物市场-市场动态

糖尿病和癌症发生率上升推动无菌注射药物市场的成长

糖尿病和癌症等慢性病发病率的上昇在很大程度上推动了无菌注射药物市场的成长。国际糖尿病联盟报告称，全球约有 5.37 亿成年人患有糖尿病，增加了对有效注射治疗的需求。同样，世界卫生组织强调，癌症是全球主要死亡原因之一，估计仅 2020 年就有 1,000 万人死亡。慢性病盛行率的激增推动了对先进、可靠的注射药物的需求，这些药物可以提供精确、有效的治疗选择。此外，药物传输技术的进步正在提高这些注射剂的功效和安全性，进一步支持市场扩张。

无菌注射药物市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 7.5% 左右的复合年增长率成长

根据药物类型细分，单株抗体 (mAb) 预计将在 2023 年显示最大的市场份额

根据给药途径细分，静脉注射 (IV) 是 2023 年的主导类型

依药物类别细分，2023年肿瘤药物为主导类型

按地区划分，北美是 2023 年的主要收入来源

无菌注射药物市场-細項分析：

全球无菌注射药物市场根据药物类型、给药途径、药物类别、最终用户和地区进行细分。

根据药物类型，市场分为五类：单株抗体（mAb）、细胞激素、胰岛素和抗生素。单株抗体（mAb）因其在治疗癌症和自体免疫疾病方面的广泛应用而在无菌注射药物市场中占据最高优先地位。胰岛素在糖尿病管理中发挥关键作用，其次是疫苗、细胞激素和抗生素。

根据给药途径，市场分为三类：静脉注射、肌肉注射和皮下注射。静脉给药是无菌注射药物市场的重中之重，因为它在急性病症中起效快且有效。其次是皮下注射，因为它易于在慢性治疗中使用，其次是针对特定应用的肌肉注射。

无菌注射药物市场 - 地理洞察

北美因其先进的医疗基础设施、创新医疗技术的高度采用以及对药物研发的大量投资而引领市场。尤其是美国，在庞大的患者群体和健全的医疗保健系统的推动下，对无菌注射剂的需求量很大。欧洲紧随其后，得到德国、法国和英国等国家强大的医疗保健系统的支持，并且越来越关註生物製剂和个人化医疗。由于慢性病发病率上升、医疗基础设施不断扩大以及中国和印度等国家医疗保健支出的增加，亚太地区正在经历快速增长。拉丁美洲、中东和非洲是新兴市场，由于医疗设施的改善和先进治疗意识的增强而显示出潜力。

无菌注射药物市场-竞争格局：

辉瑞公司、强生公司和罗氏公司等主要製药公司利用其在药物开发和製造方面的丰富专业知识来提供先进的无菌注射剂，从而引领市场。这些公司正在大力投资研究，以开发新配方并改进现有产品，以满足对慢性病有效治疗日益增长的需求。此外，随着公司旨在扩大其产品组合和市场占有率，策略併购也很常见。新创企业也正在进入市场，提供新颖的解决方案，并透过专业产品瞄准利基市场。遵守严格的监管标准并确保高品质生产的需求进一步塑造了竞争环境，从而推动了无菌注射技术的持续创新和改进。

最新进展：

2024 年 6 月，Sharp Services 宣布在宾州 Macungie 进行重大扩建，增加 157,500 平方英尺，以增强其无菌注射能力。该设施将满足对生物製剂和注射药物不断增长的需求，预计将增加 75-100 名新员工。

2023年7月，药明康德在中国无锡市启动了全自动化效能无菌注射生产线，年产能为1,200万支。该设施拥有先进的隔离系统，可确保品质并最大限度地减少各种剂型生产过程中的污染。

目录

第一章：无菌注射药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类型分類的无菌注射药物市场片段
    • 按给药途径分類的无菌注射药物市场片段
    • 按药物类别分類的无菌注射药物市场片段
    • 最终使用者的无菌注射药物市场片段
    • 按国家/地区分類的无菌注射药物市场片段
    • 按地区分類的无菌注射药物市场片段
  • 竞争洞察

第 3 章：无菌注射药物主要市场趋势

  • 无菌注射药物市场驱动因素
    • 市场驱动因素的影响分析
  • 无菌注射药物市场限制
    • 市场限制影响分析
  • 无菌注射药物市场机会
  • 无菌注射药物市场未来趋势

第 4 章：无菌注射药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：无菌注射药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：无菌注射药物市场格局

  • 2023 年无菌注射药物市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：无菌注射药物市场 - 依药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 单株抗体 (mAb)
    • 细胞因子
    • 胰岛素
    • 疫苗
    • 抗生素

第 8 章：无菌注射药物市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 静脉注射 (IV)
    • 肌肉注射 (IM)
    • 皮下注射（SC）
    • 其他的

第 9 章：无菌注射药物市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 治疗药物
    • 抗凝血剂
    • 肿瘤药物
    • 心血管药物
    • 抗感染药

第 10 章：无菌注射药物市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 专科诊所
    • 门诊手术中心
    • 研究所

第 11 章：无菌注射药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美无菌注射药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类型）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲无菌注射药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类型）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区无菌注射药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类型）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲无菌注射药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类型）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲无菌注射药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - 无菌注射药品产业

  • 竞争仪表板
  • 公司简介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • Baxter International Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Fresenius Kabi AG
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Mylan NV (now part of Viatris)
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3749

REPORT HIGHLIGHT

Sterile Injectable Drugs Market size was valued at USD 585,123.76 Million in 2023, expanding at a CAGR of 7.5% from 2024 to 2032.

The Sterile Injectable Drugs Market, comprising pharmaceuticals administered via injection under sterile conditions, is expanding due to the increasing prevalence of chronic diseases and the demand for precision therapies. The rise in conditions such as diabetes and cancer, coupled with advancements in drug delivery technologies, is fueling market growth. For example, the International Diabetes Federation estimates that over 537 million adults globally have diabetes, highlighting the significant need for effective injectable treatments. Additionally, advancements in sterile injectable technology are improving the efficiency and safety of drug administration, further driving market potential. However, challenges such as stringent regulatory requirements and high production costs can constrain market expansion. Opportunities exist in the form of growing investments in biologics and the development of advanced drug delivery systems.

Sterile Injectable Drugs Market- Market Dynamics

Rising Diabetes and Cancer Rates Fueling Growth in the Sterile Injectable Drugs Market

The growth of the Sterile Injectable Drugs Market is significantly driven by the rising incidence of chronic diseases such as diabetes and cancer. The International Diabetes Federation reports that approximately 537 million adults worldwide are living with diabetes, increasing the demand for effective injectable treatments. Similarly, the World Health Organization highlights that cancer is one of the leading causes of death globally, with an estimated 10 million deaths in 2020 alone. This surge in chronic disease prevalence is driving the need for advanced and reliable injectable drugs that can offer precise and efficient treatment options. Additionally, advancements in drug delivery technologies are improving the efficacy and safety of these injectables, further supporting market expansion.

Sterile Injectable Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.5% over the forecast period (2024-2032)

Based on Drug Type segmentation, Monoclonal Antibodies (mAbs) were predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Intravenous (IV) was the leading type in 2023

Based on Drug Class segmentation, Oncology Drugs was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Sterile Injectable Drugs Market- Segmentation Analysis:

The Global Sterile Injectable Drugs Market is segmented based on Drug Type, Route of Administration, Drug Class, End-User, and Region.

The market is divided into five categories based on Drug Type: Monoclonal Antibodies (mAbs), Cytokines, Insulin, and Antibiotics. Monoclonal Antibodies (mAbs) hold the highest priority in the Sterile Injectable Drugs Market due to their broad application in treating cancers and autoimmune diseases. Insulin follows for its critical role in diabetes management, with Vaccines, Cytokines, and Antibiotics being secondary.

The market is divided into three categories based on the Route of Administration: Intravenous, Intramuscular, and Subcutaneous. Intravenous administration is the highest priority in the Sterile Injectable Drugs Market due to its rapid onset and effectiveness in acute conditions. Subcutaneous is next for its ease of use in chronic treatments, followed by Intramuscular for specific applications.

Sterile Injectable Drugs Market- Geographical Insights

North America leads the market due to its advanced healthcare infrastructure, high adoption of innovative medical technologies, and substantial investment in drug research and development. The United States, in particular, shows a high demand for sterile injectables, driven by the large patient population and robust healthcare system. Europe follows closely, supported by strong healthcare systems in countries such as Germany, France, and the UK, and an increasing focus on biologics and personalized medicine. The Asia-Pacific region is witnessing rapid growth due to the rising incidence of chronic diseases, expanding healthcare infrastructure, and increased healthcare spending in countries like China and India. Latin America and the Middle East & Africa are emerging markets, showing potential due to improving healthcare facilities and growing awareness of advanced treatments.

Sterile Injectable Drugs Market- Competitive Landscape:

Major pharmaceutical companies such as Pfizer Inc., Johnson & Johnson, and Roche are leading the market, leveraging their vast expertise in drug development and manufacturing to deliver advanced sterile injectables. These companies are investing heavily in research to develop new formulations and improve existing products, addressing the increasing demand for effective treatments for chronic conditions. Additionally, strategic mergers and acquisitions are common as companies aim to expand their product portfolios and market presence. Emerging players are also entering the market, offering novel solutions and targeting niche segments with specialized products. The competitive environment is further shaped by the need to comply with rigorous regulatory standards and ensure high-quality production, driving continuous innovation and improvements in sterile injectable technologies.

Recent Developments:

In June 2024, Sharp Services announced a significant expansion in Macungie, Pennsylvania, adding 157,500 square feet to enhance its sterile injectable capabilities. This facility will support increased demand for biologics and injectable medicines, anticipating the addition of 75-100 new employees.

In July 2023, WuXi STA launched a fully automated potency sterile injectable manufacturing line in Wuxi City, China, with an annual capacity of 12 million units. The facility features advanced isolation systems, ensuring quality and minimizing contamination during the production of various dosage forms.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL STERILE INJECTABLE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Baxter International Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V. (now part of Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Monoclonal Antibodies (mAbs)
  • Cytokines
  • Insulin
  • Vaccines
  • Antibiotics

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Others

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Therapeutic Drugs
  • Anticoagulants
  • Oncology Drugs
  • Cardiovascular Drugs
  • Anti-Infective Drugs

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Research Institutes

GLOBAL STERILE INJECTABLE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Sterile Injectable Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Sterile Injectable Drugs Market Snippet by Drug Type
    • 2.1.2. Sterile Injectable Drugs Market Snippet by Route of Administration
    • 2.1.3. Sterile Injectable Drugs Market Snippet by Drug Class
    • 2.1.4. Sterile Injectable Drugs Market Snippet by End-User
    • 2.1.5. Sterile Injectable Drugs Market Snippet by Country
    • 2.1.6. Sterile Injectable Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Sterile Injectable Drugs Key Market Trends

  • 3.1. Sterile Injectable Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Sterile Injectable Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Sterile Injectable Drugs Market Opportunities
  • 3.4. Sterile Injectable Drugs Market Future Trends

4. Sterile Injectable Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Sterile Injectable Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Sterile Injectable Drugs Market Landscape

  • 6.1. Sterile Injectable Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Sterile Injectable Drugs Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Monoclonal Antibodies (mAbs)
    • 7.1.3. Cytokines
    • 7.1.4. Insulin
    • 7.1.5. Vaccines
    • 7.1.6. Antibiotics

8. Sterile Injectable Drugs Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Intravenous (IV)
    • 8.1.3. Intramuscular (IM)
    • 8.1.4. Subcutaneous (SC)
    • 8.1.5. Others

9. Sterile Injectable Drugs Market - By Drug Class

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 9.1.2. Therapeutic Drugs
    • 9.1.3. Anticoagulants
    • 9.1.4. Oncology Drugs
    • 9.1.5. Cardiovascular Drugs
    • 9.1.6. Anti-Infective Drugs

10. Sterile Injectable Drugs Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Ambulatory Surgical Centers
    • 10.1.5. Research Institutes

11. Sterile Injectable Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Sterile Injectable Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Sterile Injectable Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Sterile Injectable Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Sterile Injectable Drugs Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Sterile Injectable Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Sterile Injectable Drugs Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca plc
    • 12.2.4. Baxter International Inc.
    • 12.2.5. Eli Lilly and Company
    • 12.2.6. F. Hoffmann-La Roche Ltd.
    • 12.2.7. Fresenius Kabi AG
    • 12.2.8. GlaxoSmithKline plc
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Merck & Co., Inc.
    • 12.2.11. Mylan N.V. (now part of Viatris)
    • 12.2.12. Novartis AG
    • 12.2.13. Pfizer Inc.
    • 12.2.14. Sanofi S.A.
    • 12.2.15. Sun Pharmaceutical Industries Ltd.
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us